Evidence map›Paper›PMID 41674964›Full record

ArticleTranslational cancer research2026

Secretogranin II serves as a potential prognostic biomarker and correlates with the immune microenvironment in pancreatic neuroendocrine tumors.

Wuhan Yang, Linghuan Xu, Hui Li, Shubin Wang, Hao Guo, Jiaqi Zhang, Li Peng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wuhan Yang *Department of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Linghuan Xu *Department of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hui LiDepartment of Biochemistry and Molecular Biology, Hebei Medical University, Shijiazhuang, China.
Shubin WangDepartment of General Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Hao GuoDepartment of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jiaqi ZhangDepartment of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Li PengDepartment of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic neuroendocrine tumors (pNETs) present diagnostic and therapeutic challenges because of their rarity and heterogeneity. This study aimed to identify key genes involved in the development of pNETs and potentially effective prognostic biomarkers. Methods: We analyzed three datasets from the Gene Expression Omnibus, which included 135 pNET and 13 normal tissues, to identify secretogranin II ( Results: Conclusions: These findings indicate that

Indexed as

immune microenvironmentPancreatic neuroendocrine tumors (pNETs)prognosissecretogranin II (SCG2)

Identifiers

PMID41674964
PMCPMC12885914

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.